The ventricular isoform of human cardiac regulatory light chain (HCRLC) has been shown to be one of the sarcomeric proteins associated with familial hypertrophic cardiomyopathy (FHC), an autosomal dominant disease characterized by left ventricular and/or septal hypertrophy, myofibrillar disarray, and sudden cardiac death. Our recent studies have demonstrated that the properties of isolated HCRLC could be significantly altered by the FHC mutations and that their detrimental effects depend upon the specific position of the missense mutation. This report reveals that the Ca 2؉ sensitivity of myofibrillar ATPase activity and steady-state force development are also likely to change with the location of the specific FHC HCRLC mutation. The largest effect was seen for the two FHC mutations, N47K and R58Q, located directly in or near the single Ca 2؉ -Mg 2؉ binding site of HCRLC, which demonstrated no Ca 2؉ binding compared with wild-type and other FHC mutants (A13T, F18L, E22K, P95A). These two mutants when reconstituted in porcine cardiac muscle preparations increased Ca 2؉ sensitivity of myofibrillar ATPase activity and force development. These results suggest the importance of the intact Ca 2؉ binding site of HCRLC in the regulation of cardiac muscle contraction and imply its possible role in the regulatory light chain-linked pathogenesis of FHC.The regulatory light chain (RLC) 1 of myosin is a major regulatory subunit of smooth-muscle and non-muscle myosins and a modulator of the troponin (Tn) -controlled regulation of the striated muscle contraction. The crystal structures of chicken skeletal S1 (1) and the regulatory domain of scallop myosin, consisting of one RLC, one essential light chain (ELC), and a part of the myosin heavy chain (2), have revealed that the RLC is localized at the head-rod junction of the myosin heavy chain and, together with the ELC, stabilizes the ␣-helical neck of the myosin head. The N terminus of RLC is noncovalently bound to the myosin heavy chain between Asn-825 and Leu-842, whereas its C terminus wraps around the region located between Glu-808 and Val-826 of the myosin heavy chain (1). The N-terminal domain of the RLC contains a divalent cationbinding site, located in the first helix-loop-helix motif, which binds both Ca 2ϩ and Mg 2ϩ (Fig. 1A). The N-terminal region of RLC also contains the myosin light chain kinase-specific phosphorylation site (Ser-15), which is located in the proximity of the cation-binding site (3).Recent studies have revealed that the ventricular RLC is one of the sarcomeric proteins associated with familial hypertrophic cardiomyopathy (FHC) (4 -6). FHC is an autosomal dominant disease characterized by left ventricular hypertrophy, myofibrillar disarray, and sudden cardiac death. It is caused by missense mutations in various genes that encode for -myosin heavy chain (7), myosin-binding protein C (8), ventricular RLC and ELC (4 -6, 9), troponin T (10), troponin I (11), troponin C (TnC) (12), ␣-tropomyosin (13), actin (14), and titin (15). Depending on the affecte...